BioMedNewsBreaks

WednesdayFeb 12, 2025 2:05 pm

BioMedNewsBreaks – RenovoRx Inc. (NASDAQ: RNXT) Announces $12.1M Underwritten Public Offering

RenovoRx (NASDAQ: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath(R), a novel, FDA-cleared delivery platform, recently announced the pricing and closing of a firm commitment, underwritten public offering of 11,523,810 shares of its common stock at a price to the public of $1.05 per share. Of the approximately $12.1 million in gross proceeds, RenovoRx intends to use the net for working capital and general corporate purposes, including continued progression of its Phase III TIGeR-PaC study and the continued development and execution of commercial sales and marketing activities for RenovoCath as a standalone device. Titan Partners…

Continue Reading

TuesdayFeb 11, 2025 3:30 pm

BioMedNewsBreaks — Titan Partners Group Launches Equity Research Platform Led by Dr. Boris Peaker

Titan Partners, a division of American Capital Partners, today announced the launch of its Equity Research Division with the appointment of Boris Peaker, Ph.D., CFA, as managing director and senior equity research analyst. Dr. Peaker brings 17 years of experience in healthcare equity research and will lead the firm's research initiatives in the healthcare sector, focusing on biotechnology. “The launch of our research platform, spearheaded by Dr. Peaker, marks an important milestone in Titan’s growth,” said Jason Sands, co-founder and partner at Titan. “Our mission has always been to build a business around fundamentally strong and scientifically compelling stories. Dr.…

Continue Reading

TuesdayFeb 11, 2025 1:30 pm

BioMedNewsBreaks — Adageis Seizing Opportunity in AI-Driven Healthcare Innovation

Adageis is positioned to capitalize as artificial intelligence (“AI”) plays a crucial role in meeting quality metrics, reducing costs and improving patient outcomes in the transition toward value-based healthcare. While the sector faces challenges — such as integrating AI tools into existing systems, ensuring data security and navigating regulatory frameworks — innovators like Adageis, a forward-thinking healthcare technology company, are stepping in to bridge the gap, offering scalable solutions that align with modern needs. “Adageis is at the forefront of AI-driven healthcare innovation. Its ProActive Care Platform provides providers, clinics and health systems with tools to enhance care delivery while addressing…

Continue Reading

MondayFeb 10, 2025 2:05 pm

BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL) Subsidiary Global Telesat Communications Expands Partnership With EVERYWHERE Communications

NextPlat (NASDAQ: NXPL, NXPLW) announced that its subsidiary, Global Telesat Communications Ltd. (GTC), has partnered with EVERYWHERE Communications, Inc. to enhance mission-critical communications for enterprise, government, and humanitarian organizations across Europe. As EVERYWHERE’s preferred connectivity solutions provider in the UK and EU, GTC will help expand real-time global communications, situational awareness, and workforce safety solutions. The partnership will introduce advanced satellite hotspots, IoT connectivity, and integrated communications platforms to support operations in remote environments. To view the full press release, visit: https://ibn.fm/9Rzgm About NextPlat Corp NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and…

Continue Reading

MondayFeb 10, 2025 1:39 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at BIO CEO & Investor Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, will participate in the BIO CEO & Investor Conference in New York on Feb. 10-11, 2025. CEO John Climaco is scheduled to present on Feb. 10 at 1:15 p.m. ET in the Royale Room. Management will also be available for one-on-one meetings, with scheduling available through the BIO CEO attendee portal. To view the full press release, visit https://ibn.fm/alIXv About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary…

Continue Reading

MondayFeb 10, 2025 12:57 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Engages Enterprise Canada, Empire Market Ventures for PR, Investor Awareness

Quantum BioPharma (NASDAQ: QNTM) has retained Enterprise Canada Inc. and Empire Market Ventures, LLC to lead its public relations and investor awareness efforts. Enterprise, engaged indefinitely, will develop the company’s media strategy, while Empire, engaged for three months starting Feb. 7, 2025, will focus on investor marketing and outreach. The company highlighted progress on its key products, including unbuzzd™, a rapid alcohol detoxification beverage set for Q1 2025 availability, rekvry™, an alcohol misuse treatment, and LUCID-21-302, a potential multiple sclerosis treatment moving toward Phase 2 trials. To view the full press release, visit https://ibn.fm/BxkjT About Quantum BioPharma Ltd. Quantum BioPharma is a…

Continue Reading

FridayFeb 07, 2025 10:35 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) CEO to Present at Oppenheimer Healthcare Conference

Annovis Bio (NYSE: ANVS) a late-stage clinical drug platform company developing therapies for neurodegenerative diseases, announced that CEO Maria Maccecchini, Ph.D., will present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference on Feb. 11, 2025, from 12:40 to 1:10 p.m. ET. The virtual presentation will cover the company’s progress on its pivotal Phase 3 trial for early Alzheimer’s disease and strategic plans for a New Drug Application for buntanetap. The conference gathers industry leaders and investors to discuss key innovations and market trends in healthcare and life sciences. To view the full press release, visit https://ibn.fm/VFXm1 About Annovis Bio Inc.…

Continue Reading

ThursdayFeb 06, 2025 1:40 pm

BioMedNewsBreaks – BioAdaptives Inc. (BDPT) Announces Board Appointment of UFC Senior Executive Reed Harris

BioAdaptives (OTC: BDPT), a leading biotechnology company focused on innovative health and wellness solutions, has announced the appointment of Reed Harris to its board of advisors. Harris, the senior VP of athlete development and marketing at the Ultimate Fighting Championship (“UFC”) in Las Vegas, brings decades of experience in leadership, athlete development and business management, as well as a proven commitment to driving innovation and excellence. “Reed’s exceptional leadership, business acumen and dedication to athlete development and community service align perfectly with our mission to deliver innovative health and wellness solutions,” said Jim Keener, CEO of BioAdaptives. “His deep experience…

Continue Reading

ThursdayFeb 06, 2025 9:45 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Enrolls First Patients in Phase 3 Alzheimer’s Trial

Annovis Bio (NYSE: ANVS) announced that the first two patients have been enrolled in its pivotal Phase 3 trial evaluating buntanetap for early Alzheimer’s disease. The randomized, placebo-controlled study will assess the drug’s symptomatic and potential disease-modifying effects over 18 months. Following positive Phase 2/3 results, the trial received FDA approval and aims to enroll over 750 participants across approximately 100 U.S. sites. The company recently secured $21 million in funding to support the initial six-month phase, with the remaining study expected to be funded through warrant exercises. To view the full press release, visit https://ibn.fm/MxaD5 About Annovis Bio Inc.…

Continue Reading

WednesdayFeb 05, 2025 3:00 pm

BioMedNewsBreaks — Astiva Health’s Focus on Multilingual Support, Tailored Solutions Driving Its Success

Astiva Health now serves more than 30,000 members, an increase that reflects the growing demand for the company’s unique, culturally aligned health care model. “The increase in membership comes as Astiva earned a prestigious 4-star CMS rating for 2025, placing it among the top-rated Medicare Advantage providers in California,” reads a recent article. “This membership surge reflects the growing demand for Astiva’s culturally aligned health care model. The emphasis on multilingual support and culturally responsive services has made the company a leader in inclusive health care. In addition, partnerships with local businesses and activity centers have enabled Astiva to foster meaningful…

Continue Reading